Dexamethasone kinetics in depressed patients before and after clinical response. 1990

K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
Department of Psychiatry, University of Melbourne, Royal Melbourne Hospital, Victoria, Australia.

Dexamethasone pharmacokinetics were measured in 19 depressed patients, 10 dexamethasone suppression test (DST) nonsuppressors and nine suppressors, following a 1 mg oral dose in tablet form at 2300 h. Median dexamethasone concentrations were significantly lower in the nonsuppressors from 3-16 hr post-administration. Nonsuppressors had a significantly lower area under the curve than suppressors, and plasma clearance was significantly faster in the nonsuppressors than in the suppressors. Eleven patients, six nonsuppressors and five suppressors, agreed to a repeat DST after clinical improvement when all six nonsuppressors had normal DST responses. There were no significant differences between the median dexamethasone concentrations, or any of the pharmacokinetic parameters measured, of the "normalising" nonsuppressors and the suppressors. Dexamethasone kinetics were altered in depressed nonsuppressors but became normal with remission of depressive symptoms and normalisation of the DST response.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
March 1984, Archives of general psychiatry,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
March 2002, Biological psychiatry,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
February 1984, The American journal of psychiatry,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
January 1986, Journal of affective disorders,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
April 1971, Archives of general psychiatry,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
January 1977, Psychoneuroendocrinology,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
July 1983, Journal of steroid biochemistry,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
April 1990, The American journal of psychiatry,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
January 1985, Psychiatric medicine,
K P Maguire, and V M Tuckwell, and I Schweitzer, and J W Tiller, and B M Davies
January 1989, Biological psychiatry,
Copied contents to your clipboard!